Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01101594 · ClinicalTrials.gov registry record · Phase 1
A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
A Phase 1 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT01101594 is a Phase 1 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 17 participants.
The verdict
NCT01101594, a Phase 1 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
This study is a Ph I trial to test the safety of the study drug, hLL1-DOX at different dose levels in patients with recurrent multiple myeloma. HLL1 is also known as milatuzumab and is attached to doxorubicin in this clinical trial.
Interventions
- DRUG hLL1-DOX (the doxorubicin conjugate of milatuzumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2010-07 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01101594
The ClinicalTrials.gov registry entry for NCT01101594 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which hLL1-DOX (the doxorubicin conjugate of milatuzumab) is the first listed.
NCT01101594 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01101594 about?
NCT01101594 is a clinical study titled "A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma". This study is a Ph I trial to test the safety of the study drug, hLL1-DOX at different dose levels in patients with recurrent multiple myeloma. HLL1 is also known as milatuzumab and is attached to doxorubicin in this clinical trial.
What is the current status of trial NCT01101594?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2010-07. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01101594?
The interventions under investigation include: hLL1-DOX (the doxorubicin conjugate of milatuzumab) (DRUG).
Who is sponsoring clinical trial NCT01101594?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.